Abstract 798
Background
TGCT is a rare, locally aggressive neoplasm of the joint/tendon sheath associated with colony-stimulating factor 1 (CSF1) overexpression. No systemic therapy is approved. Pex, a selective inhibitor of CSF1 receptor, KIT, and FLT3-ITD, showed tumor responses in TGCT in 3 phase I studies, and significant response by Response Evaluation Criteria in Solid Tumors v1.1 (39% vs 0%; P < 0.0001) and improved functional outcomes vs placebo in a phase III study (ENLIVEN, NCT02371369). Here we report treatment-emergent hepatic ARs across TGCT studies.
Methods
Patients (pts) ≥18 y had symptomatic, unresectable TGCT; surgery was not recommended and/or was associated with potentially worse function or severe morbidity. Hepatic ARs were assessed by type and magnitude of liver test abnormalities.
Results
In 130 pts assessed for hepatic ARs from the ENLIVEN and phase I extension (PLX108-01, NCT01004861) studies, mean Pex duration was 75 wk (range, 2.14-259.14); 10 additional Pex-treated pts from 2 other phase I studies are included in the table (N = 140). Hepatic ARs were of 2 types: (1) aminotransferase elevations, which were frequent, dose-dependent, and related to CSF1 receptor inhibition, and (2) mixed or cholestatic hepatotoxicity, which was uncommon, idiosyncratic, and rarely serious (Table). All serious hepatic ARs developed in the first 8 wk of treatment. Four serious but nonfatal mixed and cholestatic cases with increased bilirubin (1 ductopenia) resolved after 1-7 mo. In non-TGCT pts (N = 658), 2 severe cases of liver toxicity (1 leading to liver transplant, 1 death with ongoing cholestasis and tumor progression) were observed with Pex.Table:
1696P
Frequency of Liver Test Abnormalities | |||||
Clinical Parameter | Phase III ENLIVEN Randomized (1000 mg/d)* n = 61 | Phase III ENLIVEN Crossover (800 mg/d)* n = 30 | Phase I PLX108-01 TGCT Cohort (1000 mg/d)* n = 39 | Other Phase I† (600 or 800 mg/d)* n = 10 | Total‡N = 140 |
Aminotransferase elevations, n (%) | |||||
ALT or AST | |||||
≥1 to < 3 × ULN ≥3 to < 5 × ULN ≥5 to < 10 × ULN ≥10 to < 20 × ULN ≥20 × ULN | 48 (79) 8 (13) 7 (11) 3 (5) 2 (3) | 21 (70) 3 (10) 2 (7) 1 (3) 0 | 27 (69) 4 (10) 2 (5) 2 (5) 0 | 6 (60) 2 (20) 0 0 0 | 102 (73) 17 (12) 11 (8) 6 (4) 2 (1) |
Mixed or cholestatic hepatotoxicity, n (%) | |||||
ALT or AST ≥3 ×, TBIL ≥2 ×, and ALP ≤2 × ULN (Hy’s law) | 0 | 0 | 0 | 0 | 0 |
ALT or AST ≥3 ×, TBIL ≥2 ×, and ALP ≥2 × ULN | 3 (5) | 0 | 1 (3)§ | 1 (10) | 5 (4)§ |
TBIL ≥2 × ULN (in absence of ALT ≥3 × or ALP >2 × ULN) | 0 | 0 | 1 (3) | 0 | 1 (1) |
Pex starting dose.
†Includes 1 TGCT pt receiving 600 mg/d in NCT02734433 and 9 TGCT pts receiving 800 mg/d in NCT03291288. ‡Mean Pex duration of all studies was 71 wk (range, 2.14-259.14).
§Includes 1 TGCT pt with a single time-point elevation of TBIL considered unrelated to treatment. ALP = alkaline phosphatase; ALT = alanine aminotransferase; AST = aspartate aminotransferase; TBIL = total bilirubin; ULN = upper limit of normal.
Conclusions
Pex is the first systemic therapy assessed in a randomized placebo-controlled study showing significantly improved tumor response and clinical benefit in locally advanced TGCT. With liver test monitoring, Pex may offer a relevant treatment option for select pts with symptomatic TGCT.
Clinical trial identification
NCT02371369, NCT02734433, NCT03291288, NCT01004861.
Editorial acknowledgement
Phillip Giannopoulos, PhD, SciStrategy Communications.
Legal entity responsible for the study
Overall abstract: Daiichi Sankyo, Inc. Individual studies: NCT02371369 – Daiichi Sankyo, Inc., NCT01004861 – Plexxikon Inc., NCT02734433 – Daiichi Sankyo Co., Ltd., NCT03291288 – Daiichi Sankyo, Inc.
Funding
Overall abstract funded by Daiichi Sankyo, Inc. Individual studies: NCT02371369 – Daiichi Sankyo, Inc., NCT01004861 – Plexxikon Inc., NCT02734433 – Daiichi Sankyo Co., Ltd., NCT03291288 – Daiichi Sankyo, Inc.
Disclosure
S. Bauer: Advisory / Consultancy, Research grant / Funding (self): Blueprint Medicines; Advisory / Consultancy: Deciphera; Advisory / Consultancy, Research grant / Funding (institution): Novartis; Honoraria (self): PharmaMar; Advisory / Consultancy: ADC Therapeutics; Advisory / Consultancy, CME-educational presentations: Lilly; Advisory / Consultancy: Janssen-Cilag; Advisory / Consultancy: Bayer; Advisory / Consultancy: Daiichi Sankyo; Advisory / Consultancy: Nanobiotix; Research grant / Funding (self), Investigator-initiated trial: Incyte; Officer / Board of Directors, Member of External Advisory Board for "Off-label use in oncology": Federal Ministry of Health. J.H. Lewis: Advisory / Consultancy, Travel / Accommodation / Expenses: Daiichi Sankyo; Speaker Bureau / Expert testimony, Travel / Accommodation / Expenses: Gilead. H. Gelderblom: Research grant / Funding (institution), Licensing / Royalties: Daiichi Sankyo; Licensing / Royalties: Boehringer Ingelheim; Licensing / Royalties: Pfizer; Licensing / Royalties: Novartis; Licensing / Royalties: PharmaMar; Licensing / Royalties: Five Prime; Licensing / Royalties: Amgen. M. van de Sande: Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo. S. Stacchiotti: Honoraria (self): Takeda; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): Lilly; Honoraria (self), Advisory / Consultancy, Research grant / Funding (institution): PharmaMar; Advisory / Consultancy, Research grant / Funding (institution): Bayer; Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo; Advisory / Consultancy, Research grant / Funding (institution): Epizyme; Advisory / Consultancy: Immunedesign; Advisory / Consultancy: Maxivax; Advisory / Consultancy, Research grant / Funding (institution): Karyopharm; Research grant / Funding (institution): Advenchen; Research grant / Funding (institution): Novartis; Research grant / Funding (institution): Pfizer. J.H. Healey: Advisory / Consultancy: Stryker; Advisory / Consultancy: Daiichi Sankyo; Advisory / Consultancy: Agios; Research grant / Funding (self): Illuminoss. W.D. Tap: Shareholder / Stockholder / Stock options: Certis Oncology Solutions; Shareholder / Stockholder / Stock options: Atropos Therapeutics; Honoraria (self), Advisory / Consultancy: Eli Lilly; Honoraria (self), Advisory / Consultancy: EMD Serono; Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self), Advisory / Consultancy: Eisai; Honoraria (self), Advisory / Consultancy: Janssen; Honoraria (self), Advisory / Consultancy: Immune Design; Honoraria (self), Advisory / Consultancy: Adaptimmune; Honoraria (self), Advisory / Consultancy: Daiichi Sankyo; Honoraria (self), Advisory / Consultancy: Blueprint; Honoraria (self), Advisory / Consultancy: Loxo; Honoraria (self), Advisory / Consultancy: GlaxoSmithKline; Honoraria (self), Advisory / Consultancy: Agios Pharmaceuticals; Honoraria (self), Advisory / Consultancy: NannoCarrier; Advisory / Consultancy: Plexxikon Pharmaceuticals; Licensing / Royalties, Companion Diagnostic for CDK4 inhibitors: Companion Diagnostic for CDK4 inhibitors. A.J. Wagner: Honoraria (self): Novartis; Advisory / Consultancy, Research grant / Funding (institution): Daiichi Sankyo; Advisory / Consultancy, Research grant / Funding (institution): Eli Lilly; Advisory / Consultancy, Research grant / Funding (institution): Five Prime; Advisory / Consultancy: Nanosphere; Research grant / Funding (institution): Plexxikon; Research grant / Funding (institution): Karyopharm; Research grant / Funding (institution): Celldex; Research grant / Funding (institution): Aadi Bioscience. A. Lopez Pousa: Research grant / Funding (self): CEBIOTEX. M. Druta: Honoraria (self), Advisory / Consultancy, Travel / Accommodation / Expenses: Daiichi Sankyo; Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony: Eisai. C. Lin: Honoraria (self), Advisory / Consultancy: Novartis; Honoraria (self): Roche; Travel / Accommodation / Expenses: BeiGene; Research grant / Funding (institution): Daiichi Sankyo. A. Yver: Shareholder / Stockholder / Stock options, Full / Part-time employment: Daiichi Sankyo. D.E. Shuster: Shareholder / Stockholder / Stock options, Full / Part-time employment: Daiichi Sankyo; Shareholder / Stockholder / Stock options: Pfizer; Shareholder / Stockholder / Stock options: Bristol-Myers Squibb; Shareholder / Stockholder / Stock options: Merck; Shareholder / Stockholder / Stock options: Regeneron; Shareholder / Stockholder / Stock options: Exelixis. J. McGill: Advisory / Consultancy, Full / Part-time employment: Daiichi Sankyo. X. Gu: Shareholder / Stockholder / Stock options, Full / Part-time employment: Daiichi Sankyo; Shareholder / Stockholder / Stock options, Full / Part-time employment, Immediate family member: PTC Therapeutics. L.D. DeLeve: Honoraria (self): Pfizer; Honoraria (self): Boehringer Ingelheim; Advisory / Consultancy: Daiichi Sankyo; Advisory / Consultancy: AbbVie; Advisory / Consultancy: SeaGen; Licensing / Royalties, Univ and I have filed provisional patent: University of Southern California. All other authors have declared no conflicts of interest.
Resources from the same session
5683 - Prevention of chemoradiation-related mucositis in patients with head and neck cancer using dexamethasone-based mouthwash: A phase II randomized double-blind, placebo-controlled study
Presenter: Naiyarat Prasongsook
Session: Poster Display session 1
Resources:
Abstract
5437 - Salivary cytokines and oral mucosa cells apoptosis in patients during hematopoietic cell transplantation: possible relationship with oral mucositis
Presenter: Luciana Corrêa
Session: Poster Display session 1
Resources:
Abstract
1483 - A randomized trial of sodium alginate prevention of radiation-induced esophagitis in patients with locally advanced NSCLC receiving concurrent chemoradiotherapy: OLCSG1401
Presenter: Toshihide Yokoyama
Session: Poster Display session 1
Resources:
Abstract
2047 - Taste and smell alterations (TSAs) in patients (pts) with stage II-III colon cancer (CC): a pilot within the PROTECT study
Presenter: Jeroen Derksen
Session: Poster Display session 1
Resources:
Abstract
5984 - Clinical characteristics are associated with acupuncture treatment response for xerostomia in cancer patients
Presenter: Wenli Liu
Session: Poster Display session 1
Resources:
Abstract
2845 - Psychosocial Distress of Adolescent and Young Adults with Cancer at Diagnosis: A Case-Matched Retrospective Cohort of 2045 Patients in British Columbia.
Presenter: Alannah Smrke
Session: Poster Display session 1
Resources:
Abstract
724 - Accuracy of distress thermometer to measure cancer-related mood disorders in Chinese patients with cancer
Presenter: Sudip Thapa
Session: Poster Display session 1
Resources:
Abstract
2357 - Modalities of biosimilar filgrastim use in clinical practice in >1000 patients receiving chemotherapy regimens with a rest period of ≤14 days: the TOPAZE study
Presenter: Jean Marc Phelip
Session: Poster Display session 1
Resources:
Abstract
1426 - The Effect of Increasing Doses of Pegfilgrastim (Peg) on Thrombocytopenia (T) in Breast Cancer (BC) Patients (pts) Receiving Taxotere (Doc), Doxorubicin, Cyclophosphamide (TAC) and Plinabulin (Plin)
Presenter: Douglas Blayney
Session: Poster Display session 1
Resources:
Abstract
712 - The use of intravenous ferric carboxymaltose without erythropoiesis-stimulating agents in the treatment of anemia in cancer patients undergoing chemotherapy with or without radiotherapy
Presenter: Hikmat Abdel-Razeq
Session: Poster Display session 1
Resources:
Abstract